Stay updated on Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.

Latest updates to the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check15 days agoChange DetectedDifference0.3%
- Check23 days agoChange DetectedThe page has been updated to reflect the latest version of the study protocol, now listed as v2.15.0, and it has removed detailed descriptions of the study's inclusion and exclusion criteria for participants with relapsed or refractory primary mediastinal large B-cell lymphoma and Richter syndrome.SummaryDifference24%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check44 days agoChange DetectedDifference0.2%
Stay in the know with updates to Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Relapsed Mediastinal Lymphoma Clinical Trial page.